BiotechTube

Duloxetine 60 mg + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fibromyalgia

Conditions

Fibromyalgia

Trial Timeline

Mar 1, 2012 → Dec 1, 2013

NCT ID
NCT01552057

About Duloxetine 60 mg + Placebo

Duloxetine 60 mg + Placebo is a phase 3 stage product being developed by Shionogi for Fibromyalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT01552057. Target conditions include Fibromyalgia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01552057Phase 3Completed

Competing Products

20 competing products in Fibromyalgia

See all competitors
ProductCompanyStageHype Score
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
DS-5565 + PlaceboDaiichi SankyoPhase 3
77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
ASP8062 + PlaceboAstellas PharmaPhase 2
52
ASP0819 + PlaceboAstellas PharmaPhase 2
52
DuloxetineShionogiPhase 3
77
zonisamideEisaiApproved
85
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
DuloxetineEli LillyApproved
85
duloxetine hydrochloride + placeboEli LillyApproved
85
duloxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyApproved
85
Treatment for FibromyalgiaEli LillyPre-clinical
23
Duloxetine + PlaceboEli LillyPhase 3
77
duloxetine + placeboEli LillyPhase 3
77
Eszopiclone + placeboSumitomo PharmaApproved
85

Other Products from Shionogi

Naldemedine + PlaceboApproved
85
Rosuvastatin + HMG CoA inhibitorApproved
85
StatinApproved
85
CefiderocolApproved
85
Duloxetine + Pregabalin + PlaceboApproved
85